Latest from Alaric DeArment
The recent US presidential election was foremost on many speakers’ minds at the Galien Forum, with many expressing uncertainty about what a new Trump administration will bring in areas ranging from the Inflation Reduction Act (IRA) to funding for the National Institutes of Health.
The drug maker said in its third quarter earnings report that competition from other therapeutic classes, particularly bispecifics, resulted in a slight decline of sales for the CAR-T.
The otherwise encouraging data were marred by one patient death, but the company attributed it to the busulfan conditioning regimen and not BEAM-101.
The biotech company is pushing the anti-PD-L1xVEGF-A bispecific antibody into Phase III, where it has potential to beat Akeso/Summit’s ivonescimab to market.
Third quarter sales for PAH drug Winrevair came in better than expected, while issues in China continued weighing on Gardasil.
Panels at the recent BioFuture conference focused on the next breakthroughs in areas such as oncology and neurodegenerative diseases, continuing challenges to GLP-1 agonists, financing and how use of AI is taking shape.